Do anticholinergics affect reaction time? A possible impact on the course of rehabilitation

NeuroRehabilitation

Volumn 27, Issue 2, 2010, Pages 141-145

  Karataş, Gülçin Kaymak ^a   Günendi, Zafer ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

cholinergic antagonists; oxybutynin; Reaction time; tolterodine

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HAND MUSCLE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PERCEPTION DISORDER; RESPONSE TIME;

ADMINISTRATION, ORAL; ADULT; BENZHYDRYL COMPOUNDS; CHOLINERGIC ANTAGONISTS; CRESOLS; CROSS-OVER STUDIES; ELECTRIC STIMULATION; ELECTROMYOGRAPHY; FEMALE; HAND; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCLE, SKELETAL; NEUROPSYCHOLOGICAL TESTS; PHENYLPROPANOLAMINE; REACTION TIME; REFERENCE VALUES;

EID: 77957278987     PISSN: 10538135     EISSN: None     Source Type: Journal    
DOI: 10.3233/NRE-2010-0590     Document Type: Article

References (24)

1. S.G. Anagnostaras, G.G. Murphy, S.E. Hamilton, S.L. Mitchell, N.P. Rahnama, N.M. Nathanson and A.J. Silva, Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice, Nat Neurosci 6 (2003), 51-58. (Pubitemid 36026332)
2. J. Botwinick and L.W. Thompson. Premotor and motor components of reaction time, J Exp Psychol 71 (1966), 9-15.
3. D.A. Crabtree and L.R. Antrim, Guidelines for measuring reaction time, Percept Mot Skills 66 (1988), 363-370.
4. R. Dickstein, S. Hocherman, G. Amdor and T. Pillar, Reaction andmovement times in patients with hemiparesis for unilateral and bilateral elbow flexion, Phys Ther 73 (1993), 374-385. (Pubitemid 23157414)
5. A.Diokno andM. Ingber, Oxybutynin in detrusor overactivity, Urol Clin N Am 33 (2006), 439-445.
6. C.A. Donnellan, L. Fook, P. McDonald and J.R. Playfer, Lesson of the week: Oxybutynin and cognitive function, BMJ 315 (1997), 1363-1364. (Pubitemid 27499744)
7. R.M. Eglen, Muscarinic receptor subtypes in neuronal and nonneuronal cholinergic function, Auton Autocoid Pharmacol 26 (2006), 219-233. (Pubitemid 43898622)
8. Z. Gunendi, O.O. Taşkiran and M. Beyazova. What is the optimal repetition number in electromyographic reaction time studies? Clin Biomech 20 (2005), 754-758. (Pubitemid 40917246)
9. T. Hasbroucq, P. Rihet, O. Blin and C.A. Possamai, Seratonin and human information processing: Fluvoxamine can improve reaction time performance, Neurosci Lett 229 (1997), 204-208. (Pubitemid 27316082)
10. T. Hasbroucq, C. Tandonnet, J. MicallefRoll, O. Blin and C.A. Possamai, An electromyographic analysis of the effect of levodopa on the response time of healthy subjects, Psychopharmacology 165 (2003), 313-316. (Pubitemid 36197607)
11. J.A. Kanofsky and V.W. Nitti, Tolterodine for treatment of overactive bladder, Urol Clin N Am 33 (2006), 447-453.
12. G.G.Kay,M.B.AbouDonia, W.S.Messer,D.G.Murphy, J.W. Tsao and J.G. Ouslander, Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients, J Am Geriatr Soc 53 (2005), 2195-2201.
13. Y. Kutukcu, W.R. Marks, Jr., D.S. Goodin and M.J. Aminoff, Simple and choice reaction time in Parkinson s disease, Brain Res 815 (1999), 367-372. (Pubitemid 29225283)
14. M. Matsui, S. Yamada, T. Oki, T. Manabe, M.M. Taketo and F.J. Ehlert, Functional analysis of muscarinic acetylcholine receptors using knockoutmice, Life Sci 75 (2004), 2971-2981. (Pubitemid 39330580)
15. A.C. Neubauer and E. Knorr, Elementary cognitive processes in choice reaction time tasks and their correlations with intelligence, Person Individ Diff 23 (1997), 715-728. (Pubitemid 127165481)
16. T. Oka, K. Nakano, T. Kirimoto and N. Matsuura, Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats, Jpn J Pharmacol 87 (2001), 27-33. (Pubitemid 32958600)
17. T. Oki, A. Kageyama, Y. Takagi, S. Uchida and S. Yamada, Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder, J Urol 177 (2007), 766-770. (Pubitemid 46053995)
18. P. Rihet, C.A. Possamai, J. MicallefRoll, O. Blin and T. Hasbroucq, Dopamine and human information processing: A reaction time analysis of the effects of levodopa in healthy subjects, Psychopharmacology 163 (2002), 62-67. (Pubitemid 34985313)
19. R. Scheife and M. Takeda, Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly, Clin Ther 27 (2005), 144-153. (Pubitemid 40462007)
20. T. Sugiyama, Y.C. Park and T. Kurita, Oxybutynin disrupts learning and memory in the rat passive avoidance response, Urol Res 27 (1999), 393-395. (Pubitemid 29526147)
21. M. Suzuki, Y. Noguchi, H. Okutsu, A. Ohtake andM. Sasamata, Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test, Eur J Pharmacol 557 (2007), 154-158. (Pubitemid 46186296)
22. A. Todorova, B. VonderheidGuth and W. Dimpfel, Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system, J Clin Pharmacol 41 (2001), 636-644. (Pubitemid 32493358)
23. J.W. Tsao and K.M. Heilman, Transient memory impairment and hallucinations associated with tolterodine use, N Engl J Med 349 (2003), 2274-2275.
24. K.B. Womack and K.M. Heilman, Tolterodine and memory: Dry but forgetful, Arch Neurol 60 (2003), 771-773.